跳至主要内容
临床试验/NCT05522998
NCT05522998已完成4 期

Efficacy and Safety of Ciprofol for the Induction of General Anesthesia in Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy

The Third People's Hospital of Chengdu1 个研究点 分布在 1 个国家目标入组 212 人开始时间: 2023年1月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
212
试验地点
1
主要终点
The rate of successful anesthesia induction

研究概览

简要总结

To evaluate the efficacy and safety of ciprofol for the induction of general anesthesia in obese patients undergoing laparoscopic sleeve gastrectomy. A randomized, parallel, propofol injection positive control study will be conducted to select obese patients who will undergo laparoscopic sleeve gastrectomy in the author's hospital. To evaluate the efficacy and safety, the main observation index, secondary observation indexes, safety evaluation indexes, and the incidence of postoperative adverse reactions will be recorded and compared between the two groups.

详细描述

To evaluate the efficacy and safety of ciprofol for the induction of general anesthesia in obese patients undergoing laparoscopic sleeve gastrectomy. A randomized, parallel, propofol injection positive control study will be conducted to select obese patients who will undergo laparoscopic sleeve gastrectomy in the author's hospital. To evaluate the efficacy and safety, the following indexes will be recorded and compared between the two groups.

  • The main observation index:(1) The rate of successful anesthesia induction
  • Secondary observation indexex:(1) Time from initial administration of study drug to loss of consciousness; (2) Time from initial administration of study drug to disappearance of eyelash reflex; (3) Changes in bispectral index(BIS) values during anesthesia induction
  • Safety evaluation indexes:(1) Adverse events; (2) Intubation response rate; (3) Vital signs; (4) Evaluation of injection pain
  • Adverse events to be focused on:(1)The incidence of blood pressure reduction requiring treatment during anesthesia induction; (2) The incidence of respiratory depression

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 < age ≤ 65, regardless of gender;
  • ASA is classified as grade I-III;
  • BMI≥35kg/m2
  • Obese patients who need laparoscopic sleeve gastrectomy under general anesthesia;
  • The subjects voluntarily participated in the trial and signed the informed consent.

排除标准

  • Contraindications to general anesthesia;
  • Accompanied by infectious heart disease such as myocarditis or endocarditis, septicemia;
  • Brain injury, possible intracranial hypertension, cerebral aneurysm, cerebrovascular accident history and central nervous system diseases: mental system diseases (schizophrenia, mania, insanity, etc.) and long-term history of taking psychotropic drugs, or other diseases that hinder the measurement of BIS value;
  • Acute heart failure, unstable angina pectoris, myocardial infarction within 6 months before screening, resting ECG heart rate ≤ 50 beats / min, third degree atrioventricular block and other serious arrhythmias, serious heart valve disease, QTc: male ≥ 450ms, female ≥ 470ms;
  • Abnormal liver and kidney function (ALT or AST ≥ 2.5 times the upper limit of normal value, TBIL ≥ 1.5 times the upper limit of normal value), abnormal renal function (bun or urea ≥ 1.5 times the upper limit of normal value, cr> the upper limit of normal value, or dialysis treatment within 28 days before operation), or obvious abnormal coagulation function (pt/ aptt/tt higher than the upper limit of normal value), anemia or thrombocytopenia (HB ≤ 90g/l, PLT ≤ 80 × 109/L)
  • Those whose blood pressure was not satisfactorily controlled (SBP ≥ 160mmhg and / or DBP ≥ 100 mmHg in sitting position during screening period);
  • SBP in sitting position during screening period ≤ 90mmHg;
  • Diabetes subjects whose blood glucose was not satisfactorily controlled (fasting blood glucose ≥ 11.1mmol/l in the screening period and / or random blood glucose ≥ 13.6 mmol/l);
  • Have a history of drug abuse and alcoholism within 2 years before the screening period. Alcoholism is defined as regular drinking for more than 14 times / week (once =150 ml wine or 360 ml beer or 45 ml spirits);
  • The subjects who were judged to have difficulty in respiratory management were rated as grade IV by modified Mahalanobis score;
  • Known or suspected allergy or contraindication to various components of the study drug or other benzodiazepines, opioids, propofol, muscle relaxants, etc;
  • Pregnant or lactating women or subjects with birth plan within 6 months (including men);
  • Those who participated in any clinical trial as subjects within 3 months before enrollment;
  • Other circumstances determined by the researcher as unsuitable for inclusion.

研究组 & 干预措施

Ciprofol Group

Experimental

Experimental drug: Ciprofol; Dosage form: injection; Specification: 20ml: 50mg; Frequency and duration: intravenous infusion with micropump, anesthesia induction dose 0.4-0.5mg/kg, Administration for 30s (± 5S)

干预措施: Ciprofol (Drug)

Propofol Group

Active Comparator

Experimental drug: Propofol; Dosage form: injection; Specification: 20ml: 200mg; Frequency and duration: intravenous infusion with micropump, anesthesia induction dose 2-2.5mg/kg, Administration for 30s (± 5S)

干预措施: Propofol (Drug)

结局指标

主要结局

The rate of successful anesthesia induction

时间窗: Through study completion, an average of 1 year

The criteria for success are to meet the following two requirements at the same time: 1) successful induction (i.e. improved investigator awake / sedation score (MOAA / S) ≤ 1) after the administration of the study drug (at most 2 additional times are allowed); 2) No alternative anesthetics were used.

次要结局

  • Time to LOC(During anesthesia induction, an average of 10 minutes)
  • Time to disappearance of eyelash reflex(During anesthesia induction, an average of 10 minutes)
  • BIS(During anesthesia induction, an average of 10 minutes)

研究者

发起方
The Third People's Hospital of Chengdu
申办方类型
Other
责任方
Principal Investigator
主要研究者

Xiaowei Chi

Principal Investigator

The Third People's Hospital of Chengdu

研究点 (1)

Loading locations...

相似试验